Don-A

Quick links to important sections

Don-A

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Don-A

Don-A is a medicinal product defined by its active ingredient, Domperidone, and its dual role as a prokinetic and antiemetic agent. It functions to normalize digestive tract movement and alleviate symptoms of nausea. The drug is often commercially positioned to address discomfort associated with slow gastric motility, a distinctive focus.


Quick Facts: Don-A Identity

Property Description
Active ingredient Domperidone (INN)
Form Tablet, Oral suspension
Pharmacological class Dopamine receptor antagonist
General purpose Relieves nausea and promotes gastric emptying
Origin Synthetic (Benzimidazolone derivative)

What Type of Medicine is Don-A?

Don-A is classified as a synthetic, single-ingredient medicine that functions as a selective peripheral dopamine receptor antagonist. The active compound, Domperidone, is a Benzimidazolone derivative that was chemically synthesized to target specific dopamine receptors, particularly those located outside the central nervous system. This classification as a dopamine receptor antagonist is based on its targeted action, which primarily affects the digestive system and the chemoreceptor trigger zone, ensuring the product's effect is focused on the mechanisms that inhibit normal gastrointestinal function.


Don-A Composition and General Purpose

The composition of Don-A centers exclusively on the active ingredient Domperidone, and it is most commonly available for oral administration as a tablet or an oral suspension. As a single-ingredient formulation, all therapeutic effects are attributed to this specific compound. Its mechanism is associated with effectiveness in controlling symptoms of nausea and vomiting through its prokinetic effect. The drug’s availability in multiple dosage forms, including the film-coated tablet and the oral suspension, is typical for flexible ingestion. Ultimately, the design and composition of Don-A link directly to its general purpose: to restore coordinated gastrointestinal contractions and neutralize the signals that lead to feelings of nausea and issues with slow digestive motility, such as the uncomfortable fullness after eating.

What side effects are possible with Don-A?

Possible Side Effects and Safety Information

The official safety profile for Don-A (Domperidone) is structured to communicate the medicine's documented adverse reactions and significant regulatory constraints. The most critical focus is the potential for serious, dose-dependent effects on the heart.


Official Classification of Adverse Reactions

Adverse reactions are formally grouped by the body system affected, with frequency classifications derived from regulatory summaries, such as those published by the European Medicines Agency (EMA) and Health Canada. Certain effects are classified as Uncommon (may affect up to 1 in 100 people), while serious events are often classified as Not known (frequency cannot be estimated from available data).

System-Organ Class Examples of Documented Adverse Reactions
Nervous System Headache, drowsiness, extrapyramidal disorders
Reproductive System Galactorrhea, breast pain, menstrual irregularities
Gastrointestinal Dry mouth, diarrhea

Serious Safety Considerations

The most serious reactions documented in official regulatory sources relate to cardiac function, including the risk of QTc prolongation, ventricular arrhythmias, Torsade de Pointes, and sudden cardiac death. These serious adverse events are highly correlated with the dose and the duration of use.


Population and Exposure Restrictions

Official labeling defines specific safety constraints:

  • Duration and Dose: Use is restricted to the lowest effective dose for the shortest possible duration, generally not exceeding one week. The risk of serious cardiac events increases with daily oral doses greater than 30 mg.
  • Population Restrictions: The medicine is explicitly contraindicated in patients over 60 years of age and in those with moderate or severe hepatic impairment. It is also restricted in individuals with pre-existing QTc prolongation, certain underlying cardiac diseases, or significant electrolyte disturbances.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Don-A (Domperidone) overdose focuses on specific central nervous system (CNS) and severe cardiovascular risks. Manifestations documented in official labeling include somnolence, agitation, altered consciousness, disorientation, confusion, and convulsions. Overexposure may also lead to extrapyramidal reactions, such as uncontrolled movements or abnormal posture.

Critically, regulators caution that overdose is associated with the risk of serious ventricular arrhythmias, QT interval prolongation, and potentially sudden cardiac death. Immediate medical attention must be sought straight away if an overdose is suspected.

Management is strictly supportive and symptomatic because no specific antidote is known. Due to the cardiac risk, continuous ECG monitoring should be undertaken. The medicine must be stopped if any sign of cardiac arrhythmia occurs.

Population-specific notes highlight that a higher risk of serious cardiac effects is observed in patients older than 60 years and those taking doses greater than 30 mg. Furthermore, the risk of undesirable neurological effects, particularly extrapyramidal symptoms, is higher in younger children.

Therapeutic Uses of Don-A

Main Uses of Don-A

Don-A is a pharmacological treatment primarily utilized for the management of cognitive symptoms associated with dementia. Its main application is in the symptomatic treatment of Alzheimer's disease, ranging from mild to severe stages. The medication is designed to address the decline in cognitive function by influencing the chemical messengers in the brain responsible for memory and thought processes.

Therapeutic Indications

The medication is indicated for patients experiencing cognitive impairment due to neurodegenerative conditions. Its use is centered on:

  • Mild to Moderate Alzheimer’s Disease: Managing memory loss and confusion in the early and middle stages of the condition.
  • Severe Alzheimer’s Disease: Supporting cognitive maintenance in advanced stages where functional decline is more pronounced.

Benefits and Expected Outcomes

The primary objective of Don-A therapy is to stabilize or slow the progression of cognitive symptoms rather than to provide a cure for the underlying disease. The benefits observed during treatment typically focus on quality of life and the maintenance of daily functioning.

Impact on Cognitive Function

Don-A works by increasing the concentration of acetylcholine in the brain. This can lead to several clinical benefits for the patient:

  • Memory Retention: Improved ability to recall recent events or recognize familiar faces and places.
  • Attention and Focus: Enhanced concentration and a reduction in the frequency of periods of confusion.
  • Language and Communication: Support for clearer expression and better comprehension during social interactions.

Behavioral and Functional Support

Beyond direct cognitive metrics, the medication may contribute to broader stability in a patient's daily routine. This includes:

  • Maintenance of Daily Activities: Assisting patients in performing routine tasks such as dressing, eating, or managing personal hygiene for a longer period.
  • Behavioral Stability: Potential reduction in the restlessness or agitation often associated with progressive cognitive decline.
  • Social Engagement: Facilitating continued participation in family life and social environments by supporting mental clarity.

Regulatory References

  1. Summary of Product Characteristics (SPC) reviewed by the Irish Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Don-A? (Domperidone)

The eligibility for Don-A is strictly governed by regulatory guidelines, primarily focusing on cardiac risk and specific medical conditions. Use is permitted only for Adults and Adolescents 12 years of age or older weighing 35 kg or more.


Absolute Contraindications (Must Not Use)

Don-A is officially contraindicated (prohibited) for use in the following populations, as stated in regulatory labeling:

  • Patients with moderate or severe hepatic (liver) impairment.
  • Patients with known cardiac risk factors, including a history of prolonged QTc interval, congestive heart failure, or significant electrolyte disturbances (e.g., low potassium or magnesium).
  • Patients with a prolactin-releasing pituitary tumor.
  • Patients experiencing gastro-intestinal hemorrhage, obstruction, or perforation, where stimulating gut movement could be harmful.

Restrictions and Special Populations

  • Pediatric Use: The use of Don-A is not recommended or contraindicated in children under 12 years or adolescents weighing less than 35 kg.
  • Geriatric Use: Caution is advised for patients over 60 years.
  • Pregnancy/Lactation: Use during pregnancy is generally not recommended. Use during breastfeeding is restricted because the drug passes into breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Don-A (Domperidone) is defined by strict constraints aimed at mitigating cardiac risks. Co-administration is contraindicated with two main categories of medicinal products: those that are potent CYP3A4 inhibitors and those known to prolong the QTc interval. The core pharmacokinetic interaction involves the inhibition of the CYP3A4 enzyme, leading to multi-fold increases in Domperidone plasma concentration. This increased exposure, combined with the additive pharmacodynamic effect on cardiac repolarization, increases the risk of ventricular arrhythmias.

Interaction Type Interacting Categories (Examples) Interaction Outcome
Pharmacokinetic / Metabolic Potent CYP3A4 Inhibitors (e.g., certain antifungals, macrolide antibiotics) Contraindicated; Increased drug exposure (AUC/Cmax).
Pharmacodynamic QTc-prolonging medicines (e.g., certain antiarrhythmics, antipsychotics) Contraindicated; Additive QTc prolongation risk.

Don-A is also classified as a P-glycoprotein (P-gp) substrate. Regarding food intake, the drug's oral bioavailability is affected, with official recommendations to administer the oral form before meals. Grapefruit juice is also contraindicated. A higher interaction-related risk is noted in patients over 60 years and those with moderate or severe hepatic impairment, where use is also prohibited. The overall interaction profile is structurally based on these formal restrictions, as stated in regulatory drug labels.

Mechanism of Action

The mechanism of Don-A is defined by its action as a selective Dopamine D2 receptor antagonist in peripheral sites. The influence of this mechanism is directed at two distinct physiological domains: the modulation of digestive motility and the signal pathway for the emetic reflex.

Peripheral Modulation of Upper GI Motility

The mechanism involves the antagonism of D2 receptors on nerve endings in the walls of the stomach and duodenum. This action removes the inhibitory effect of dopamine on the release of acetylcholine (ACh), thereby enhancing the excitatory cholinergic pathway in the enteric nervous system. This cascade results in an increased amplitude and coordination of peristalsis and accelerated gastric emptying.

Suppression of the Emetic Reflex Signal

Simultaneously, the drug antagonizes D2 receptors located within the Chemoreceptor Trigger Zone (CTZ), a region outside the main blood-brain barrier. By blocking D2 receptor activation here, the mechanism suppresses the CTZ's sensitivity to chemical signals in the bloodstream. This targeted suppression of emetic signaling interrupts the initiation signal for physical expulsion at the CTZ.

Dosage and Administration Information

Administration Guidelines for Don-A

Don-A administration is standardized for short-term use, focusing on established administration principles. The primary route of administration is oral, available in tablets and oral suspension forms. The standardized dosing schedule for adults and adolescents (12 years of age or older and weighing 35 kg or more) is 10 mg per dose, taken up to three times per day. This schedule establishes a strict maximum daily dose of 30 mg when administered orally.


Timing and Duration

Administration should occur before meals (typically 15 to 30 minutes prior), as food may delay its absorption. The overall administration pattern is short-term; the treatment duration must generally not exceed seven consecutive days for acute use. If a dose is missed, the missed dose is omitted, and the next scheduled dose is taken at the regular time without doubling the amount.


Preparation and Adjustments

If the oral suspension is used, an appropriate measuring device is used to ensure accurate administration. Population-Specific Adjustments apply to certain patient groups. For individuals with severe renal impairment, the dosing frequency is reduced. In pediatric patients weighing less than 35 kg, a precise weight-based dosing of 0.25 mg/kg per dose is calculated; standard tablets are generally unsuitable for this group due to the difficulty of accurate dose division.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Don-A

Evidence for Use in Symptomatic Osteoarthritis of the Knee

Don-A, containing Glucosamine Sulfate, has been studied for use in patients with mild to moderate osteoarthritis of the knee. The main body of research consists of Randomized Controlled Trials (RCTs), where researchers compare the medicine against a placebo or an inactive treatment. These trials are used in research exploring how symptoms change over time in patients with this specific joint condition.

Researchers examined patient-reported outcomes describing perceived discomfort, often using validated scales to measure changes in pain intensity. They also monitored outcomes reflecting daily functioning or activity level. Scientific reviews reported that the patterns observed in the studies, such as changes in pain and function scores, often showed difference measurements compared to placebo or other inactive treatments. However, findings were mixed across various studies. The evidence contributes to understanding symptom patterns in patients with osteoarthritis, but research does not determine whether an individual will respond similarly.


Long-Term Studies and Follow-Up Data

The majority of clinical trials for Don-A were designed to observe symptomatic responses over defined time intervals that are generally considered intermediate. The evidence derived from settings with varying symptom burdens frequently relies on follow-up periods ranging from several weeks up to approximately six months.

This means that long-term outcomes are not fully established. While research provides insight into short-term changes and how symptoms evolved in the observed populations during the trial period, there is limited information for long-term outcomes regarding the durability of the symptomatic observations or what happens after extended use. Research regarding how symptoms evolved in the observed populations over many years is not well characterized in the existing evidence base.


What is Still Uncertain in the Research Landscape

The evidence base for Don-A, while including RCTs, still presents several research limitation frames. Scientific reviews frequently point out that the findings were mixed when trials using different versions of the active ingredient were compared. Furthermore, observations regarding the difference measurements in patient symptoms compared to placebo have been heterogeneous, which contributes to the overall view that certainty remains low in some areas. Scientific reviews note that the overall evidence quality varies across studies, and many regulatory summaries note that the follow-up durations were limited, contributing to the uncertainty surrounding any potential long-term patterns related to symptom patterns.

Key Studies & References

  1. Glucosamine and Chondroitin for Osteoarthritis | NCCIH - NIH
  2. Summary of Product Characteristics (SPC) - Glucosamine sulfate 500mg Film-coated Tablets (HPRA)
  3. Summary of Product Characteristics (SPC) - Dona 1500 mg Powder for Oral Solution (HPRA)
  4. Effectiveness and Safety of Glucosamine in Osteoarthritis: A Systematic Review - MDPI

Frequently Asked Questions (FAQ)

Common questions about Don-A (FAQ)

Q: How long until I start feeling the effects of Don-A?

A: Official product information notes that food consumption may delay the medicine's absorption. For this reason, official guidance on timing is provided in the drug's administration guidelines. However, the time until the effects begin to be felt is not specifically detailed in the official patient information.

Q: What happens if I accidentally miss a dose of Don-A?

A: If a dose is missed, official instructions state that the dose should be simply omitted. The guidance is to resume the regular schedule by taking the next dose as scheduled, without doubling the amount to compensate for the missed dose.

Q: Is it normal to feel [mild side effect] when first starting Don-A?

A: Documented adverse reactions, such as headache, drowsiness, and dry mouth, are listed in official safety information. These effects are classified by how often they occur; for example, some effects are classified as 'Uncommon,' meaning they may affect up to 1 in 100 people. The full list of potential side effects is available in the official product information for a complete overview.

Q: Does Don-A interact with common supplements like multivitamins?

A: Official safety information focuses on contraindicating specific classes of medicines, such as strong CYP3A4 inhibitors, QTc-prolonging medicines, and grapefruit juice. Information on interactions with common non-prescription supplements like multivitamins is not specifically detailed.

Q: Can Don-A affect my ability to drive or operate machinery?

A: Dizziness and drowsiness (somnolence) are documented adverse effects of Don-A. If a person experiences these effects, they should avoid driving or operating machinery until they understand how the medicine affects their ability to concentrate and react.

Q: What are the signs of a serious reaction to Don-A?

A: If symptoms that suggest an abnormal heart rhythm are experienced, such as dizziness, fainting (syncope), or noticing heart palpitations, prompt medical attention is indicated. These can be signs of serious cardiac reactions, such as QTc prolongation, as noted in official safety documentation.

Q: Can I take Don-A if I drink alcohol occasionally?

A: Official patient safety information advises avoiding alcohol consumption while taking the medicine. Alcohol may worsen certain side effects, such as increasing feelings of sleepiness or potentially contributing to an irregular heartbeat.

Q: Are there any foods or drinks I should avoid while on Don-A?

A: Grapefruit juice is contraindicated (prohibited) because it can significantly increase the concentration of the medicine in the body. Additionally, Don-A is to be taken before meals, as food can interfere with its absorption.

Q: Is Don-A safe for elderly patients?

A: Official information indicates that the risk of serious cardiac events may increase in patients over 60 years of age. For this population, use is restricted, requiring the lowest effective dose for the shortest possible duration.

Q: Can children take Don-A, and is the dosage different?

A: Use is generally not recommended for children under 12 years of age or adolescents weighing less than 35 kg. For children and adolescents weighing less than 35 kg where licensed, a precise weight-based dosing is required, often making the standard tablets unsuitable due to the difficulty of accurate dose division.

Q: Is it safe to take Don-A during pregnancy?

A: Official information indicates that use during pregnancy is generally not recommended. Use is restricted, and any decision on use requires a healthcare provider's assessment of potential risks versus benefits. The medicine also passes into breast milk, restricting its use during breastfeeding.

Q: How long does Don-A stay in your system after stopping?

A: The half-life of the drug—the time it takes for half of the medicine to be eliminated from the body—is approximately 7 to 9 hours in healthy adults. Official information notes that this time may be longer in individuals who have severe kidney problems.

Q: Why is Don-A sometimes prescribed for different conditions?

A: Currently, the authorized regulatory use of Don-A is strictly limited to the relief of symptoms related to nausea and vomiting. This limitation aligns with safety constraints established by major regulatory bodies.

Q: Are there any long-term side effects associated with Don-A use?

A: Regulatory reviews state that treatment duration must generally not exceed seven consecutive days for acute use. The risk of serious cardiac events, which are the most critical safety concerns, increases with the duration of use.

Q: Can Don-A impact sleep patterns?

A: Drowsiness (somnolence) is a documented side effect that affects the nervous system. While the official information notes drowsiness, the specific effects on a patient's overall sleep quality or long-term sleep patterns are not detailed.

Q: How often do people need to adjust their Don-A dosage?

A: Dosage frequency must be reduced for individuals who have severe renal (kidney) impairment. Otherwise, dose adjustments are determined by a healthcare professional, based on finding the lowest effective dose for the shortest period.

Q: Is it possible for Don-A to stop working after a while?

A: Regulatory bodies have noted that there is limited evidence to support the long-term effectiveness of the drug for certain indications, leading to restrictions on duration of use.

Q: How do I know if Don-A is actually helping my condition?

A: The authorized indication for Don-A is to relieve symptoms of nausea and vomiting. Therefore, the primary way to assess its effectiveness is by monitoring the control and reduction of these specific symptoms.

Q: Can I take Don-A if I have a history of liver or kidney issues?

A: Official information states that the medicine is contraindicated (prohibited) for use in patients with moderate or severe hepatic (liver) impairment. For patients with severe renal (kidney) impairment, the dosing frequency must be reduced.

Q: Why does Don-A need to be taken at the same time every day?

A: It is important to try and take each dose at the scheduled time to ensure consistent drug exposure in the body. Consistent timing helps maintain the prescribed dosing regimen and therapeutic effect.

Q: Is it possible to be allergic to Don-A?

A: Yes, official regulatory information states that Don-A is contraindicated in patients with known hypersensitivity to the active ingredient, domperidone, or any of the other ingredients in the product.

Q: What steps should I take if I suspect an interaction with another drug?

A: Official guidance indicates that if a person suspects a drug interaction or adverse drug reaction, they should discontinue taking the medicine and seek prompt medical advice.

Q: What is the difference between Don-A tablets and capsules, if both exist?

A: Don-A is officially authorized and available most commonly as a tablet or an oral suspension. Official regulatory documents do not list an authorized capsule formulation for this medicine.

Q: What percentage of people experience side effects with Don-A?

A: Regulatory documents do not provide a single overall percentage for side effects. Instead, side effects are classified into frequency categories—such as Common, Uncommon, or Not known—based on the available clinical data.

Q: Is it necessary to have follow-up appointments while on Don-A?

A: Official guidance indicates that regular review by a healthcare professional is important. This allows for monitoring of effectiveness, adverse effects, and cardiovascular risk factors, particularly when treatment duration is extended.

Q: Can Don-A be used with other medications for the same condition?

A: Co-administration with other medicines must be carefully evaluated. The drug is strictly contraindicated with potent CYP3A4 inhibitors and QTc-prolonging medicines due to safety risks. Use with other antiemetics requires careful consideration from a healthcare professional.

Q: Can Don-A cause changes in mood or behavior?

A: Side effects on the central nervous system, such as headache and drowsiness, have been documented in official sources. However, specific changes in mood or behavior are not commonly listed as adverse reactions in regulatory summaries.

Q: What is the typical duration of treatment with Don-A?

A: The maximum recommended treatment duration should not usually exceed one week (seven consecutive days). This restriction is in place for acute use to help minimize the risk of serious cardiac adverse effects.

Q: What is still uncertain in the research landscape?

A: Scientific reviews indicate that uncertainty remains regarding long-term outcomes of the medicine. The quality of the existing evidence varies across studies, and findings often show heterogeneity when comparing changes in patient symptoms to placebo.

Q: Can Don-A be crushed or split if I have trouble swallowing pills?

A: Official product information does not provide instructions regarding crushing or splitting the tablets. Patients who have difficulty swallowing are typically advised that the readily available oral suspension form is the alternative.

How should Don-A be stored and disposed of?

How to Store and Dispose of Don-A?

The storage and disposal of Don-A (Domperidone) must follow specific regulatory requirements to maintain product stability and protect the environment. It is mandated to keep the medicine out of the sight and reach of children.


Storage Conditions

Requirement Official Regulatory Rule
Temperature Do not store above 30ºC; do not refrigerate or freeze.
Protection Store in the original package to protect tablets from light and moisture.
Stability The oral suspension has an in-use shelf-life of 3 months after first opening.

Disposal Instructions

Unused or expired Don-A must be discarded according to local, regional, and national regulations. To comply with environmental protection rules, the product should not be emptied into drains or discharged into sewer systems. Patients are instructed to return any unwanted medicine to a pharmacy for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Don-A found in:

A-Z Index: